DekaBank Deutsche Girozentrale Purchases 17,085 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

DekaBank Deutsche Girozentrale lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.8% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,057,579 shares of the biopharmaceutical company's stock after purchasing an additional 17,085 shares during the period. DekaBank Deutsche Girozentrale owned about 0.17% of Gilead Sciences worth $229,294,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Brighton Jones LLC raised its stake in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after buying an additional 2,450 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth $339,000. PNC Financial Services Group Inc. raised its stake in Gilead Sciences by 0.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 393,801 shares of the biopharmaceutical company's stock worth $36,375,000 after purchasing an additional 3,626 shares during the period. Larson Financial Group LLC boosted its holdings in Gilead Sciences by 17.5% in the 4th quarter. Larson Financial Group LLC now owns 9,205 shares of the biopharmaceutical company's stock valued at $850,000 after purchasing an additional 1,370 shares during the last quarter. Finally, Personal CFO Solutions LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $207,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider directly owned 121,152 shares of the company's stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer directly owned 620,268 shares of the company's stock, valued at $68,489,992.56. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,500 shares of company stock worth $6,340,745 over the last 90 days. 0.27% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Morgan Stanley increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Trading Up 1.3%

Shares of GILD stock traded up $1.45 during trading hours on Wednesday, hitting $112.51. 1,722,199 shares of the company were exchanged, compared to its average volume of 7,675,437. The firm has a market cap of $139.96 billion, a P/E ratio of 23.68, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a 50 day simple moving average of $107.26 and a two-hundred day simple moving average of $104.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a fifty-two week low of $66.34 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm posted ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. Gilead Sciences's dividend payout ratio is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.